^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) + alrizomadlin (APG-115) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4217: Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia
Published date:
06/23/2020
Excerpt:
The results showed that HQP1351 alone exhibited potent antiproliferative activity in both cell lines in vitro, with nanomolar IC50 values . The activity was enhanced in the combination treatment with APG-115...In subcutaneous MV-4-11 xenograft model, treatment with HQP1351 or APG-115 single agents achieved T/C values of 28.6% and 59.6%, respectively . The combination achieved synergistic antitumor activity with a T/C value of 13.4%...Taken together, our data provide scientific rationale for clinical development of the combination of HQP1351 and APG-115 in FLT3-ITD mutant and TP53 wild-type AML patient.
DOI:
10.1158/1538-7445.AM2020-4217
